Welcome to our dedicated page for VERADERMICS news (Ticker: MANE), a resource for investors and traders seeking the latest updates and insights on VERADERMICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VERADERMICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VERADERMICS's position in the market.
Veradermics (NYSE: MANE) priced an upsized initial public offering of 15,077,647 shares at $17.00 per share, raising approximately $256.3 million in gross proceeds before fees. The company expects NYSE trading to begin on February 4, 2026 and closing on February 5, 2026, subject to customary conditions.
The underwriters received a 30-day option to purchase up to an additional 2,261,647 shares. Jefferies, Leerink Partners, Citigroup, and Cantor are joint book-running managers.
FAQ
What is the current stock price of VERADERMICS (MANE)?
